Literature DB >> 16325936

Comparative protein profiling identifies elongation factor-1beta and tryparedoxin peroxidase as factors associated with metastasis in Leishmania guyanensis.

John Walker1, Nathalie Acestor, Rafael Gongora, Manfredo Quadroni, Iris Segura, Nicolas Fasel, Nancy G Saravia.   

Abstract

Parasites of the Leishmania Viannia subgenus are major causative agents of mucocutaneous leishmaniasis (MCL), a disease characterised by parasite dissemination (metastasis) from the original cutaneous lesion to form debilitating secondary lesions in the nasopharyngeal mucosa. We employed a protein profiling approach to identify potential metastasis factors in laboratory clones of L. (V.) guyanensis with stable phenotypes ranging from highly metastatic (M+) through infrequently metastatic (M+/M-) to non-metastatic (M-). Comparison of the soluble proteomes of promastigotes by two-dimensional electrophoresis revealed two abundant protein spots specifically associated with M+ and M+/M- clones (Met2 and Met3) and two others exclusively expressed in M- parasites (Met1 and Met4). The association between clinical disease phenotype and differential expression of Met1-Met4 was less clear in L. Viannia strains from mucosal (M+) or cutaneous (M-) lesions of patients. Identification of Met1-Met4 by biological mass spectrometry (LC-ES-MS/MS) and bioinformatics revealed that M+ and M- clones express distinct acidic and neutral isoforms of both elongation factor-1 subunit beta (EF-1beta) and cytosolic tryparedoxin peroxidase (TXNPx). This interchange of isoforms may relate to the mechanisms by which the activities of EF-1beta and TXNPx are modulated, and/or differential post-translational modification of the gene product(s). The multiple metabolic functions of EF-1 and TXNPx support the plausibility of their participation in parasite survival and persistence and thereby, metastatic disease. Both polypeptides are active in resistance to chemical and oxidant stress, providing a basis for further elucidation of the importance of antioxidant defence in the pathogenesis underlying MCL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16325936     DOI: 10.1016/j.molbiopara.2005.10.008

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  14 in total

Review 1.  Peroxiredoxins in parasites.

Authors:  Michael C Gretes; Leslie B Poole; P Andrew Karplus
Journal:  Antioxid Redox Signal       Date:  2012-01-25       Impact factor: 8.401

2.  Cloning, expression and dynamic simulation of TRYP6 from Leishmania major (MRHO/IR/75/ER).

Authors:  G Eslami; F Frikha; R Salehi; A Khamesipour; H Hejazi; M A Nilforoushzadeh
Journal:  Mol Biol Rep       Date:  2010-12-01       Impact factor: 2.316

3.  A comparative study of type I and type II tryparedoxin peroxidases in Leishmania major.

Authors:  Janine König; Alan H Fairlamb
Journal:  FEBS J       Date:  2007-10-08       Impact factor: 5.542

4.  Transgenic, fluorescent Leishmania mexicana allow direct analysis of the proteome of intracellular amastigotes.

Authors:  Daniel Paape; Christoph Lippuner; Monika Schmid; Renate Ackermann; Martin E Barrios-Llerena; Ursula Zimny-Arndt; Volker Brinkmann; Benjamin Arndt; Klaus Peter Pleissner; Peter R Jungblut; Toni Aebischer
Journal:  Mol Cell Proteomics       Date:  2008-05-12       Impact factor: 5.911

5.  Comparative transcriptomic and proteomic analyses of Trichomonas vaginalis following adherence to fibronectin.

Authors:  Kuo-Yang Huang; Po-Jung Huang; Fu-Man Ku; Rose Lin; John F Alderete; Petrus Tang
Journal:  Infect Immun       Date:  2012-08-27       Impact factor: 3.441

Review 6.  Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis.

Authors:  Albert Schriefer; Mary E Wilson; Edgar M Carvalho
Journal:  Curr Opin Infect Dis       Date:  2008-10       Impact factor: 4.915

7.  Leishmania mitochondrial peroxiredoxin plays a crucial peroxidase-unrelated role during infection: insight into its novel chaperone activity.

Authors:  Helena Castro; Filipa Teixeira; Susana Romao; Mariana Santos; Tânia Cruz; Manuela Flórido; Rui Appelberg; Pedro Oliveira; Frederico Ferreira-da-Silva; Ana M Tomás
Journal:  PLoS Pathog       Date:  2011-10-27       Impact factor: 6.823

8.  Paromomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paromomycin -susceptible -resistant Leishmania donovani.

Authors:  Bhavna Chawla; Anupam Jhingran; Aswini Panigrahi; Kenneth D Stuart; Rentala Madhubala
Journal:  PLoS One       Date:  2011-10-27       Impact factor: 3.240

Review 9.  Leishmania RNA virus: when the host pays the toll.

Authors:  Mary-Anne Hartley; Catherine Ronet; Haroun Zangger; Stephen M Beverley; Nicolas Fasel
Journal:  Front Cell Infect Microbiol       Date:  2012-07-12       Impact factor: 5.293

10.  Protective and pathologic immune responses in human tegumentary leishmaniasis.

Authors:  Lucas P Carvalho; Sara Passos; Albert Schriefer; Edgar M Carvalho
Journal:  Front Immunol       Date:  2012-10-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.